Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 5:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,319 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Targeted agent Clear all
Completed Not applicable Interventional

Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.

NCT04828668
View directory record Official record
Conditions
Covid 19
Interventions
Targeted Wellness Formula C™ Sublingual Drops - 1200mg - 30 mL (Formula C)
Dietary Supplement
Lead sponsor
Endourage, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 30, 2026, 5:44 PM EDT
Recruiting Phase 1Phase 2 Interventional

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

NCT05842174
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Hydroxychloroquine, Lipiodol, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 1 Interventional

Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer

NCT05702424
View directory record Official record
Conditions
Solid Tumor
Interventions
IGM-7354
Drug
Lead sponsor
IGM Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Sarasota, Florida • Huntersville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

NCT00619892
View directory record Official record
Conditions
Panic Disorder
Interventions
quetiapine XR, placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 5:44 PM EDT
Not listed No phase listed Observational

QUantitative Assessment of Swallowing After Radiation (QUASAR)

NCT04359199
View directory record Official record
Conditions
Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma
Interventions
Radiation Therapy, Cetuximab, Chemotherapy, Immunotherapy
Radiation · Drug
Lead sponsor
Loren Mell, MD
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

NCT01920711
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

NCT02678312
View directory record Official record
Conditions
Pediatric Heart Failure
Interventions
LCZ696, Enalapril, Placebo of LCZ696, Placebo of Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month to 17 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 30, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional Results available

Targeted Investigation of Microbiome Elimination

NCT05177328
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
S. hominis A 9 Product, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 30, 2026, 5:44 PM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants

NCT02579265
View directory record Official record
Conditions
Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
Interventions
Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
Drug
Lead sponsor
Fresenius Kabi
Industry
Eligibility
0 Weeks and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
13
States / cities
Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 30, 2026, 5:44 PM EDT
Terminated Not applicable Interventional Results available

Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

NCT00665444
View directory record Official record
Conditions
Bipolar Disorder, Metabolic Syndrome
Interventions
Aripiprazole
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 4 Interventional Results available

Erector Spinae Versus Paravertebral Nerve Blocks for Breast Surgery

NCT03549234
View directory record Official record
Conditions
Breast Surgery
Interventions
Erector Spinae (single injection), Paravertebral (single injection)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 30, 2026, 5:44 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Reducing Arterial Inflammation Using Eplerenone and Statins in HIV

NCT07892664
View directory record Official record
Conditions
HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD), Arterial Inflammation, Heart Disease
Interventions
Eplerenone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 30, 2026, 5:44 PM EDT
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 30, 2026, 5:44 PM EDT
Completed No phase listed Observational

Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study

NCT03911466
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 2 Interventional Results available

Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer

NCT05653856
View directory record Official record
Conditions
Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions
64Cu-PSMA I&T
Drug
Lead sponsor
Curium US LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
9
States / cities
New Haven, Connecticut • Hines, Illinois • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2025 · Synced Oct 30, 2026, 5:44 PM EDT
Completed No phase listed Observational

Analysis of Reporting of Cutaneous Toxicities Associated With Immune Checkpoint Inhibitors

NCT04898751
View directory record Official record
Conditions
Cutaneous Toxicity From ICI Therapy
Interventions
Immune checkpoint inhibitor (ICI)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
2,214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Oct 30, 2026, 5:44 PM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

NCT07849231
View directory record Official record
Conditions
Myeloproliferative Neoplasms (MPNs)
Interventions
DMR-001, Ruxolitinib
Drug
Lead sponsor
Damora Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 3 Interventional

Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

NCT00369837
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
14
States / cities
Montgomery, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 30, 2026, 5:44 PM EDT
Recruiting Phase 2 Interventional

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

NCT04038502
View directory record Official record
Conditions
Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Interventions
Carboplatin, Olaparib
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
18
States / cities
West Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Phase 2 Interventional

Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer

NCT00003553
View directory record Official record
Conditions
Kidney Cancer
Interventions
HLA Matched Peripheral BLood Stem Cells
Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 30, 2026, 5:44 PM EDT
Terminated Phase 1Phase 2 Interventional

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic
Interventions
SLC-391, pembrolizumab
Drug · Biological
Lead sponsor
SignalChem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • Lafayette, Indiana • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 30, 2026, 5:44 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Intramyocardial Injection of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Repair of Hypoplastic Left Heart Syndrome

NCT03779711
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Autologous (self) mononuclear cells derived from umbilical cord blood, Stage II Surgical repair
Biological · Procedure
Lead sponsor
Timothy J Nelson, MD, PhD
Other
Eligibility
Up to 12 Months
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 30, 2026, 5:44 PM EDT
Withdrawn Phase 2 Interventional

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

NCT07428044
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 5:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Connect 'n Unite: Couples-Based HIV/STI Prevention for Drug-Involved, Black MSM

NCT01394900
View directory record Official record
Conditions
HIV, Sexually Transmitted Infections
Interventions
CNU Intervention, WP Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 30, 2026, 5:44 PM EDT